100 CARDINAL WAY, REDWOOD CITY, CA
Adverum Biotechnologies Enters Merger Agreement with Eli Lilly
Investor Presentation
End of Material Contract, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events
To Acquire Biotechnologies
Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration
Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights
News, Material Contracts
Financial Results, Press Release
Q3
Q2
Q1
FY 2024
Notice of Late Filing for Annual Report
Notice of Suspension of Duty to File Reports
Effectiveness Notice
Tender Offer Statement by Third Party
Solicitation/Recommendation Statement
Tender Offer Statement by Issuer
Schedule 14D-9C Solicitation/Recommendation Statement Communication
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
S-8 POS
Amended Tender Offer Statement by Third Party